Price$3.80-2.61 (-40.72%)
2026-03-092026-06-10
News · 26 weeks35+367%
2025-12-142026-06-07
Mix2390d
- SEC Filings10(43%)
- Other9(39%)
- Analyst1(4%)
- Earnings1(4%)
- Offering1(4%)
- M&A1(4%)
Latest news
25 items- SECSEC Form 6-K filed by Inventiva S.A.6-K - Inventiva S.A. (0001756594) (Filer)
- PRCombined General Meeting of June 30, 2026 - Availability of the Preparatory DocumentsDaix (France), New York City (New York, United States), June 9,2026 – Inventiva (NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the availability of the preparatory documents for the Combined General Meeting of June 30, 2026. Shareholders are invited to participate in the Combined General Meeting that will be held on June 30, 2026 at 2 p.m. at Hôtel Villa M, 24 – 30 Boulevard Pasteur, 75015 Paris (France). The preliminary notice of meeting comprising the agenda and the draft resolutions, as well as information on
- SECSEC Form 6-K filed by Inventiva S.A.6-K - Inventiva S.A. (0001756594) (Filer)
- SECSEC Form 6-K filed by Inventiva S.A.6-K - Inventiva S.A. (0001756594) (Filer)
- SECSEC Form 424B5 filed by Inventiva S.A.424B5 - Inventiva S.A. (0001756594) (Filer)
- SECSEC Form FWP filed by Inventiva S.A.FWP - Inventiva S.A. (0001756594) (Subject)
- PRInventiva Announces Trading Resumption of its Ordinary Shares on Euronext ParisDaix (France), New York City (New York, United States), June 2, 2026 – Inventiva (NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the trading resumption of its ordinary shares on the regulated market of Euronext in Paris as from 3:30 p.m. CEST. Trading of the ordinary shares of the Company was halted, at the Company's request, on June 2, 2026 from 9:00 a.m. CEST, in the context of the previously announced Debt Financing Transaction and Offering of American Depositary Shares in the United States (each representing
- PRInventiva Announces a Comprehensive Capital Structure Optimization including Debt and Equity Financing in Advance of the Anticipated Phase 3 ReadoutSecured a new debt financing with funds and accounts managed by BlackRock and Claret Capital Partners, respectively for up to €130 million in committed tranches, subject to conditions, plus an additional uncommitted tranche of up to €20 million, to replace its existing EIB loan ahead of maturity and extend its debt maturity profile to 2030Simplifying its capital structure with agreement to repurchase existing warrants issued in favor of the EIB, thereby eliminating 60% of the dilution protected EIB warrants (exercisable into 22.7 million shares), at a 40% discount to intrinsic value, and restructuring the remaining EIB warrants on terms that do not contain dilution protectionPriced an underw
- SECSEC Form F-3ASR filed by Inventiva S.A.F-3ASR - Inventiva S.A. (0001756594) (Filer)
- PRInventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext ParisDaix (France), New York City (New York, United States), June 2, 2026 – Inventiva (NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announces that the listing of its ordinary shares on the regulated market of Euronext Paris will be temporarily halted, at the Company's request, from the opening of the market at 9:00 a.m. CEST. This suspension comes ahead of a proposed financing transaction, details of which will be announced in a new communication of the Company. This suspension will be effective until a new communication is
- SECSEC Form 6-K filed by Inventiva S.A.6-K - Inventiva S.A. (0001756594) (Filer)
- PRInventiva Reports 2026 First Quarter Financial Information¹Cash and cash equivalents at €75.0 million, and €121.5 million in short-term deposits2 Daix (France), New York City (New York, United States), May 26, 2026 – Inventiva (NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today reported its financial information for the first quarter of 2026, including its cash, cash equivalents and revenues. Key Financial Results Cash, Cash Equivalents and Deposits As of March 31, 2026, the Company's cash and cash equivalents amounted to €75.0 million and its short-term deposits2 to €121.5 million
- SECSEC Form 6-K filed by Inventiva S.A.6-K - Inventiva S.A. (0001756594) (Filer)
- PRInventiva to Present at 2026 Jefferies Global Healthcare ConferenceDaix (France), New York (United States), May 21, 2026 – Inventiva (NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced that CEO Andrew Obenshain will present at at the upcoming 2026 Jefferies Global Healthcare Conference. The conference is being held June 2-4, 2026, in New York City. Inventiva leadership will also hold one-on-one meetings during the conference. Presentation details are as follows: Date: Wednesday, June 3, 2026Time: 5:30-6:00pm (ET) Location: New York CityWebcast link: Inventiva S.A. About Inventiv
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Inventiva S.A.SCHEDULE 13G/A - Inventiva S.A. (0001756594) (Subject)
- PRInventiva to Present Abstracts at the EASL Congress 2026Daix (France), New York City (New York, United States), May 13, 2026 – Inventiva (NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the presentation of two abstracts at the upcoming annual congress of the European Association for the Study of the Liver, EASL Congress 2026, to be held from May 27 to 30, 2026 in Barcelona. Details of the presentations are as follow: Abstract title:Lanifibranor-induced improvements in histological parameters and cardiometabolic markers in MASH are independent of weight change and close
- SECSEC Form 6-K filed by Inventiva S.A.6-K - Inventiva S.A. (0001756594) (Filer)
- PRInventiva announces filing of its 2025 Universal Registration Document and 2025 Annual Report on Form 20-FDaix (France), New York City (New York, United States), April 8, 2026 – Inventiva (Euronext Paris and NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced that it had filed its 2025 Universal Registration Document for the year ended December 31, 2025, including the management report and the annual financial report, with the French Autorité des Marchés Financiers ("AMF") and its 2025 Annual Report on Form 20-F for the year ended December 31, 2025 with the U.S. Securities and Exchange Commission ("SEC"). These documents can be accessed
- SECSEC Form 20-F filed by Inventiva S.A.20-F - Inventiva S.A. (0001756594) (Filer)
- SECSEC Form 6-K filed by Inventiva S.A.6-K - Inventiva S.A. (0001756594) (Filer)
- PRInventiva reports 2025 full year results and provides a business updateRevenues of €4.5 million for the full year of 2025Cash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits1 as at December 31, 2025Completed a U.S. registered public offering for gross proceeds of approximately $172.5 million (€149 million2)Cash runway expected until the middle of the first quarter of 20273Completed the sale of odiparcil with potential milestone payments of up to $90 million and potential royalties on future net sales, if approvedTopline results of NATiV3 Phase 3 clinical trial expected for the fourth quarter of 2026The Company will host a conference call on March 31, 2026, at 8 a.m. EDT / 2 p.m. CEST Daix (France), New York City (New York, Uni
- PRInventiva Schedules the Publication and Presentation of its 2025 Full-Year Financial ResultsDaix (France), New York (United States), March 23, 2026 – Inventiva (NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced that it will release its 2025 full-year financial results on Monday, March 30, 2026, after market close in the United States. Inventiva's management will hold a conference call in English, followed by a Q&A session, on Tuesday, March 31, 2026, at 8:00 am (New York), 2:00 pm (Paris). Participants wishing to join the conference call by phone and ask questions must register in advance here. Upon regis
- ANALYSTTruist initiated coverage on Inventiva with a new price targetTruist initiated coverage of Inventiva with a rating of Buy and set a new price target of $13.00
- PRInventiva to Participate in Four Upcoming March Investor ConferencesDaix (France), New York (United States), February 26, 2026 – Inventiva (NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced that the Company's leadership will participate in one-on-one meetings and presentations during the following upcoming investor events: TD Cowen 46th Annual Health Care Conference – March 2-4, 2026Date: Monday, March 2, 2026Time of fireside chat: 10:30am ESTLocation: Boston, Massachusetts Leerink Global Healthcare Conference – March 9-11, 2026Date: Tuesday, March 10, 2026Time of presentation: 10
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Inventiva S.A.SCHEDULE 13G/A - Inventiva S.A. (0001756594) (Subject)
IVA FAQ
7 questionsWhat does Inventiva S.A. do?
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie...Where does IVA stock trade?
Inventiva S.A. (IVA) is listed on NASDAQ.What sector and industry is IVA in?
Inventiva S.A. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Inventiva S.A. go public?
Inventiva S.A. (IVA) completed its IPO in 2020.What are analysts saying about IVA?
Inventiva S.A. has had 8 recent analyst actions on file. The most recent action was from Truist: Buy with a $1300.00 price target on 2026-03-19. Recent price targets range from $1000.00 to $2600.00.What companies are similar to IVA?
Notable peers in the same industry include GNFT (GENFIT S.A.), GLTO (Galecto Inc.), CMMB (Chemomab Therapeutics Ltd.). Compare IVA side-by-side with any of them on Quantisnow.How can I track IVA on Quantisnow?
Quantisnow aggregates Inventiva S.A.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IVA to receive live email and push alerts on every new disclosure.